J&J, Hopeful On COVID-19 Vaccine Outlook, Looks To Restore Public Confidence
Executive Summary
The company recorded $100m in revenues from the vaccine in the first quarter, before administration was paused in the US and Europe to review a rare risk of blood clots.
You may also be interested in...
J&J CEO Gorsky Handing Over The Reins To Vice Chairman Duato
Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Gorsky is stepping down due to a family health issue.
J&J CEO Gorsky Handing Over Reins To Vice Chairman Duato
Joaquin Duato has been involved for the last several years in growing J&J’s pharma and consumer businesses and has led the company’s COVID-19 efforts. Alex Gorsky is stepping down due to a family health issue.
J&J's COVID-19 Vaccine On Track To Generate $2.5bn This Year
The company's pharma revenues grew 17.2% in the second quarter against favorable comparisons and as the COVID-19 pandemic recovery continued.